
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
over 25 years ago
Decision Making at Digital Speedover 25 years ago
Mergers: Big Pharma Shrinks Someover 25 years ago
Generics: Streamline and Stimulateover 25 years ago
Grace Under Fireover 25 years ago
Get Ready to Merge or Divergeover 25 years ago
Pharma's Quantum Shuffle





